Product Description
Ertugliflozin 15mg Tablets: What the Published Guidance Says
Human and analogue insulins alongside the oral hypoglycaemics and cardiorenal-metabolic agents added to the WHO Model List in its September 2025 revision.
Before Ertugliflozin 15mg Tablets is quoted, we confirm the monograph, the strength on the artwork and the release testing required by your market — the points summarised here.
- SGLT2 inhibitors are on the Model List Section 18.5.2 lists empagliflozin as a 10 mg and 25 mg tablet for type 2 diabetes mellitus, with canagliflozin and dapagliflozin named as therapeutic equivalents. WHO eEML — Medicines for diabetes
- The scale of the access problem WHO reports that more than 800 million people were living with diabetes in 2022, with half going untreated, and that more than one billion people worldwide are affected by obesity with rates rising fastest in low- and middle-income countries. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
- September 2025 added the GLP-1 class WHO added the GLP-1 receptor agonists semaglutide, dulaglutide and liraglutide, and the dual GLP-1/GIP agonist tirzepatide, for adults with type 2 diabetes where cardiovascular disease or chronic kidney disease is established and obesity is present (BMI ≥ 30 kg/m²). WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
Each point above is reproduced because it has a practical consequence for Ertugliflozin 15mg Tablets: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Ertugliflozin 15mg Tablets — Supply Parameters
| Product Name | Ertugliflozin Tablets (Ertugliflozin 15mg Oral Tablets) |
| Specification | Each tablet contains: Ertugliflozin 15mg |
| Dosage Form | Oral Film-Coated Tablet (for oral administration) |
| Active Ingredient | Ertugliflozin |
| Pharmacological Class | Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Antidiabetic Agent) |
| Route of Administration | Oral administration (swallowed whole with water; take at approximately the same time each morning, with or without food). |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze. |
| Therapeutic group | Diabetes & Insulin — Diabetes & Insulin |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Dapagliflozin 10mg Tablets, Canagliflozin 300mg Tablets, Empagliflozin 25mg Tablets, Finerenone 20mg Tablets, Repaglinide Tablets 2mg, Sotagliflozin 400mg Tablets, Mixed Protamine Human Insulin 30R, Insulin Glargine Injection 100IU/mL 3ml Cartridge.
Quality Control, Pharmacopoeial Standards & Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Ertugliflozin 15mg Tablets follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
A typical release panel for this presentation covers:
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
- Testing for packaging integrity and seal testing
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packaging, Labelling & Export
- Pack size: Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep container tightly closed. Do not freeze..
- Shelf life: 36 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Registration, Dossier & Tender Support
The legal manufacturer named on every document for Ertugliflozin 15mg Tablets is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
Ertugliflozin 15mg Tablets is presented here against medicines for diabetes listed in the WHO Model List. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Frequently Asked Questions
What pack size is available for Ertugliflozin 15mg Tablets?
Standard commercial packaging for this line is Blister pack (PVC-Alu) or HDPE bottle, typically 30 tablets per blister pack or bottle. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Ertugliflozin 15mg Tablets?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months.
Does the batch documentation for Ertugliflozin 15mg Tablets support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 36 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Do you supply human insulin as well as analogues?
Yes. We supply human short-acting, isophane and premixed 30/70 protamine human insulin, and insulin glargine. The Model List notes that quality-assured biosimilars are included in its analogue listings.
Which SGLT2 inhibitors do you supply?
Empagliflozin, dapagliflozin, canagliflozin and ertugliflozin in tablet form. Empagliflozin is the molecule specifically listed in section 18.5.2 of the Model List, with canagliflozin and dapagliflozin named as therapeutic equivalents.
Related Diabetes & Insulin Products
- Dapagliflozin 10mg Tablets — 10mg
- Canagliflozin 300mg Tablets — 300mg
- Empagliflozin 25mg Tablets — 25mg
- Finerenone 20mg Tablets — 20mg
- Repaglinide Tablets 2mg — 2mg
- Sotagliflozin 400mg Tablets — 400mg
Browse the full Diabetes & Insulin range; all Tablets; the complete product catalogue.
Request a Quotation for Ertugliflozin 15mg Tablets
Tell us the monograph, pack size and quantity required for Ertugliflozin 15mg Tablets 15mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
- WHO eEML — Medicines for diabetes
- WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
